Tamoxifen resistance: EGFR expression in hormone receptor-positive and HER2 negative breast cancer

被引：0
|
作者：
Bae, S. Y. [1 ]
Nam, S. J. [1 ]
Lee, S. K. [1 ]
Kim, S. W. [1 ]
Lee, J. E. [1 ]
Yu, J. H. [1 ]
机构：
[1] Samsung Med Ctr, Seoul, South Korea
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.SABCS16-P6-09-36
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P6-09-36
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Podoplanin expression in cancer-associated fibroblasts predicts unfavorable prognosis in node-negative breast cancer patients with hormone receptor-positive/HER2 − negative subtype
    Yuko Tanaka
    Takashi Ohno
    Taichi Kadonaga
    Yoshiteru Kidokoro
    Makoto Wakahara
    Kanae Nosaka
    Tomohiko Sakabe
    Yoshimasa Suzuki
    Hiroshige Nakamura
    Yoshihisa Umekita
    Breast Cancer, 2021, 28 : 822 - 828
  • [42] Estrogen receptor-positive, progesterone receptor-negative breast cancer: Association with growth factor receptor expression and tamoxifen resistance
    Arpino, G
    Weiss, H
    Lee, AV
    Schiff, R
    De Placido, S
    Osborne, CK
    Elledge, RM
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (17): : 1254 - 1261
  • [43] Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer
    Ditsch, Nina
    Schmidt, Marcus
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2019, 79 (12) : 1328 - 1335
  • [44] Immune microenvironment and intrinsic subtyping in hormone receptor-positive/HER2-negative breast cancer
    Gaia Griguolo
    Maria Vittoria Dieci
    Laia Paré
    Federica Miglietta
    Daniele Giulio Generali
    Antonio Frassoldati
    Luigi Cavanna
    Giancarlo Bisagni
    Federico Piacentini
    Enrico Tagliafico
    Katia Cagossi
    Guido Ficarra
    Aleix Prat
    Pierfranco Conte
    Valentina Guarneri
    npj Breast Cancer, 7
  • [45] Current Landscape of Targeted Therapy in Hormone Receptor-Positive and HER2-Negative Breast Cancer
    Andrahennadi, Samitha
    Sami, Amer
    Manna, Mita
    Pauls, Mehrnoosh
    Ahmed, Shahid
    CURRENT ONCOLOGY, 2021, 28 (03) : 1803 - 1822
  • [46] Effect of tamoxifen after chemotherapy in hormone receptor-positive, node-negative breast cancer
    Panasci, LC
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (15) : 2392 - 2392
  • [47] Evolving treatment patterns in hormone receptor-positive, HER2-negative metastatic breast cancer
    Lankford, M. L.
    Britton, S. L.
    Buettner, A. D.
    Scharf, M.
    Tiscione, B.
    Willey, J. P.
    Mahtani, R. L.
    CANCER RESEARCH, 2019, 79 (04)
  • [48] Neoadjuvant tucidinostat combined with chemotherapy for hormone receptor-positive, HER2-negative breast cancer
    Niu, Nan
    Xue, Jinqi
    Qiu, Fang
    Chen, Guanglei
    Gu, Xi
    He, Guijin
    Cao, Shuo
    Yu, Xiaopeng
    Xu, Yongqing
    Yin, Jianqiao
    Han, Sijia
    Han, Ye
    Tang, Meiyue
    Zhao, Yafei
    Zheng, Ran
    Zheng, Xinyu
    Xu, Hong
    Liu, Caigang
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [49] Immune microenvironment and intrinsic subtyping in hormone receptor-positive/HER2-negative breast cancer
    Griguolo, Gaia
    Dieci, Maria Vittoria
    Pare, Laia
    Miglietta, Federica
    Generali, Daniele Giulio
    Frassoldati, Antonio
    Cavanna, Luigi
    Bisagni, Giancarlo
    Piacentini, Federico
    Tagliafico, Enrico
    Cagossi, Katia
    Ficarra, Guido
    Prat, Aleix
    Conte, Pierfranco
    Guarneri, Valentina
    NPJ BREAST CANCER, 2021, 7 (01)
  • [50] Neoadjuvant endocrine therapy helps identify HER2 up-regulation in patients with hormone receptor-positive HER2-negative breast cancer
    Chaudhary, Lubna N.
    Jorns, Julie M.
    Cheng, Yee Chung
    Kamaraju, Sailaja
    Gonyo, Mary Beth
    Kong, Amanda
    Patten, Caitlin
    Yen, Tina
    Cortina, Chandler
    Carson, Ebony
    Johnson, Nedra
    Bergom, Carmen
    Banerjee, Anjishnu
    Wang, Yu
    Chitambar, Christopher R.
    Rui, Hallgeir
    CANCER RESEARCH, 2021, 81 (04)
12345